Breakthrough in Japan

Mar 10, 2011

A number of Japanese pharmaceutical companies are taking a closer look at companies and universities in Medicon Valley. Swedish EXINI Diagnostics has just concluded a 24 million SEK contract with the Japanese FUJIFILM Pharma.

A contract just concluded between the Swedish EXINI Diagnostics and the Japanese pharmaceutical company FUJIFILM Pharma Co. Ltd. is the latest development in a steadily growing Japanese interest in companies and universities in Medicon Valley. For EXINI the contract is worth a potential 24 million SEK over the next three years. EXINI Diagnostics has developed software to help doctors analyse X-ray images and it is the product EXINI Bone, which FUJIFILM Pharma Co. Ltd. are now launching onto the Japanese market.

– A number of major Japanese pharmaceutical companies have all taken a closer look at biotech and medtech companies in the region. At the same time there is considerable interest in early-stage innovations from our universities, says Thomas Jonsson, Medicon Valley’s Life Science Ambassador in Japan and South Korea.

Search for In-Licensing Candidates
Significant Japanese groups such as Takeda Pharmaceutical Company Limited, Eisai Pharmaceuticals, Daaichi-Sankyo, Astellas Pharma Inc., Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma and Shionogi & CO., LTD have all shown considerable interest in the region and there have been repeated visits to Medicon Valley by Japanese companies.

Extended Arm in Japan
EXINI Diagnostics’ contract with the Japanese pharmaceutical company FUJIFILM Pharma has just been concluded as a result of close collaboration with Medicon Valley’s Life Science Ambassador in Japan. The Ambassador, Thomas Jonsson, has been assisting EXINI Diagnostics for a long time with projects relating, among other things, to development, patenting, sales and cultural barriers. These are projects which had to be completed to establish the cooperation contract. Whilst the management of EXINI Diagnostics was based in Sweden, Thomas Jonsson was able to act on behalf of EXINI Diagnostics in Japan.

– Thomas Jonsson, Life Science Ambassador in Japan, played a decisive role in our success concluding the contract with FUJIFILM Pharma. He worked on our behalf in Japan and we were able to take advantage of his presence in all matters relating to the Japanese market. Thomas Jonsson will also become an important resource for our further expansion in Japan, says Magnus Aurell, CEO of Exini Diagnostics.

Charlotte Ahlgren Moritz, Executive Vice President, Medicon Valley Alliance, points out that Japan is a large and important market within pharma, biotech and medtech.

– It is very significant that we have aroused considerable Japanese interest in Medicon Valley. Japan is a market which requires patience and a long-term strategy. However, this is not an insurmountable task, which is also confirmed by Exini’s breakthrough in Japan, says Charlotte Ahlgren Moritz.

breakthrough-in-Japan---Magnus-Aurell-218pxMagnus Aurell, CEO, EXINI Diagnostics:

– Thomas Jonsson, Life Science Ambassador in Japan, played a decisive role in our success concluding the contract with FUJIFILM Pharma.

1962Charlotte Ahlgren Moritz, Executive Vice President of Medicon Valley Alliance:

– The Ambassador Programme forms contacts and relationships which can help companies and universities in Medicon Valley establish new international collaboration. These efforts are now yielding results in Japan.

Source: Medicon Valley Alliance, 10.03.2011

[shareaholic app=”share_buttons” id=”15743046″]         

Most recent news